Intra-operative administration of taurolidine reduces level of interleukin-1 beta rather than povidone-iodine in patients with colon, gastric, and pancreatic cancer. A clinical prospective randomised multicenter trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN66478538

Enrollment

120

Registered

2006-02-17

Start date

1999-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon, gastric or pancreatic cancer Cancer 1. Malignant neoplasm of colon 2. Malignant neoplasm of stomach 3. Malignant neoplasm of pancreas

Interventions

120 Patients with colon, gastric or pancreatic cancer have been randomised between January 1999 and August 2001 to receive either taurolidine or povidone-iodine intraperitoneally during open resection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Open resection of colon, gastric, or pancreatic cancer 2. American Society of Anesthesiologists (ASA) I-III classification 3. Histopathological R0-resection

Exclusion criteria

Exclusion criteria: 1. Complete ileus 2. ASA IV classification 3. Histopathological R1- or R2-resection 4. Unknown intra-operative metastasis, peritoneal carcinomatosis, intra-abdominal abscess, sepsis or clinically relevant organ failure 5. Apparent coagulopathy

Design outcomes

Primary

Measure	Time frame
Interleukin-1 beta perioperatively measured six times	—

Secondary

Measure	Time frame
1. Evaluation of morbidity and mortality 2. Side-effects 3. Long-term follow-up after 3, 6, 12 months and 2, 3, 4 and 5 years	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 3, 2026